12 , 13 A clear trend in dose dependence was seen for the time to reach 50%, 90%, 95%, and 99% reductions in parasite density in our study ( appendix ).
← all excerpts
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.
1
—
—